Deals
Teva Said to Seek Fast EU Approval for Allergan Unit Bid
- Firms seen offering remedies to EU by Thursday p.m. deadline
- Deal would create world's largest maker of generic drugs
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. will try to win an early European Union approval for its takeover of Allergan Plc’s generics unit by making concessions to regulators this week, according to a person familiar with the matter.
Teva and Allergan will meet a Thursday midnight deadline to propose remedies aimed at allaying any EU antitrust concerns, said the person, who asked not to be named because the process is private.